Humana Inc. Q2 FY2026 Earnings Call Summary

HUM NYSE Healthcare 📅 2026-07-29 ⏱ ~60 sec read 🟡 Neutral

⏱️ 60-Second Brief Humana Inc. · Q2 FY2026

Revenue

$40.888B

AI Sentiment

🟡 Neutral

While Humana demonstrated strong operational growth and affi…

📌 Bottom Line: Humana reported strong Q2 2026 Adjusted EPS of $7.61 and robust revenue growth of 26.24%, while affirming its full-year Adjusted EPS guidance of 'at least $9.00'. The company demonstrated significant membership growth in…

🤖 AI-Assisted Summary — Produced using a custom AI pipeline by Abhi, reviewed for accuracy. · ⚠️ Not financial advice. For informational purposes only. Full Disclaimer →

✍️ EarningsBloom Editorial Team · 📅 Last updated: 2026-07-29 · 📎 Source: SEC EDGAR / Company Press Release

📋 TL;DR — What Happened

Humana reported strong Q2 2026 Adjusted EPS of $7.61 and robust revenue growth of 26.24%, while affirming its full-year Adjusted EPS guidance of 'at least $9.00'. The company demonstrated significant membership growth in Medicare Advantage and strategic expansion in CenterWell and Medicaid, signaling solid operational execution despite a downward revision in GAAP EPS guidance.

📊 Key Financial Metrics

Revenue $40.888B

EPS (Diluted) —

YoY Revenue Growth 26.24%

AI Sentiment 🟡 Neutral While Humana demonstrated strong operational growth and affirmed its Adjusted EPS guidance, the significant downward revision of GAAP EPS and the acknowledged Star Ratings headwind create a mixed outlook.

✅ What Went Well

✅ Humana delivered consolidated revenues of $40.888 billion in Q2 2026, a substantial 26.24% increase year-over-year, showcasing strong market penetration and member acquisition. Concurrently, the company reported a robust Adjusted EPS of $7.61, significantly higher than the $6.27 recorded in Q2 2025, underscoring enhanced operational efficiency and profitability in its core business.

✅ Despite external pressures and a revision to GAAP EPS, Humana confidently affirmed its full-year 2026 Adjusted EPS guidance of 'at least $9.00'. This affirmation provides investors with a stable outlook on the company's underlying earnings power and demonstrates management's ability to navigate challenges while maintaining core financial targets.

✅ The company reported strong momentum in its strategic growth areas, including an anticipated 'approximately 25 percent' growth in individual Medicare Advantage membership over 2025, driven by effective sales and retention strategies. Furthermore, its CenterWell Senior Primary Care segment saw a remarkable 27% year-to-date patient growth, adding 130,900 patients, and Humana secured a new statewide Illinois Medicaid managed care contract, highlighting successful diversification and expansion into key healthcare markets.

⚠️ Concerns & Risks

⚠️ Humana revised its full-year 2026 GAAP EPS guidance downwards to 'at least $6.52' from the previous estimate of 'at least $8.36'. This substantial reduction in GAAP earnings, while Adjusted EPS guidance remains affirmed, indicates that non-GAAP adjustments are having a considerable impact, potentially obscuring the true financial picture for some investors and raising questions about the consistency of reported earnings.

⚠️ The company explicitly stated that its FY 2026 Adjusted EPS guidance anticipates a year-over-year decline as a direct result of the Star Ratings headwind for Bonus Year (BY) 2026, even after mitigation efforts. This indicates a tangible negative impact on future quality bonus payments from CMS, which are a significant component of Medicare Advantage plan profitability, posing a clear challenge to earnings growth.

⚠️ Humana is currently involved in a lawsuit challenging the 2025 Star Ratings of its Medicare Advantage plans, with an initial court decision rejecting Humana's challenge and an appeal pending. The potential failure to prevail in this lawsuit could negatively impact 2026 quality bonus payments and significantly affect revenues, operating results, and cash flows, highlighting a persistent regulatory and legal risk that could undermine financial performance.

🔮 CEO / Management Guidance

Humana affirmed its full-year 2026 Adjusted EPS guidance of 'at least $9.00', signaling confidence in its core operational performance and strategic initiatives. However, the company revised its GAAP EPS guidance for the fiscal year 2026 downwards to 'at least $6.52' from the previous estimate of 'at least $8.36', reflecting the impact of various non-GAAP adjustments. Management anticipates that the full-year Adjusted EPS will experience a year-over-year decline primarily due to the Star Ratings headwind for Bonus Year 2026, even after accounting for mitigation efforts.

💬 Key Quote

The first half of the year went well, and we're right where we said we'd be at Investor Day last year. When we get the clinical care right and run the business more efficiently, everything else follows—stronger earnings and better health and experiences for the people we serve.” — Jim Rechtin, President and CEO

🏢 About Humana Inc.

Humana Inc. (HUM) is a publicly listed company on the NYSE exchange in the Healthcare sector. EarningsBloom tracks its quarterly earnings calls to provide free AI-generated summaries for investors.

HUM NYSE Healthcare All Humana Inc. Summaries →

📈 Want to act on this insight?

🇮🇳 Open Zerodha Account 🌱 Start with Groww 📄 Full Transcript on Seeking Alpha 📚 Learn Financial Analysis

Topics: Medicare Advantage CenterWell Growth Financial Guidance Star Ratings Impact

📁 More from Humana Inc.

View all earnings summaries for Humana Inc. →